Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib vs Cisplatin with Camrelizumab and Gemcitabine in Nasopharyngeal Carcinoma
NCT05854849Phase 3Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Rivoceranib in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Started May 2023; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT05854849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05854849.